Catherine Shu is an Oncology physician affiliated with NewYork–Presbyterian Hospital. OpenAlex indexes 291 publications with 4,380 citations (h-index 31); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
177 Fort Washington Ave
Milstein Hospital, 6th Floor, Internal Medicine
New York, NY 100323733
Telephone
212-305-6354Registry record last updated 14 Jun 2016.
Clinical trials
- Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment
Sponsor: Catherine Shu
- SGI-110 Plus Durvalumab/Tremelimumab in SCLC
Sponsor: Catherine Shu
- Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC
Sponsor: Columbia University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- F. Hoffmann-La Roche AGProgram year20255 payments
- EMD Serono, Inc.Program year20253 payments
- AstraZeneca Pharmaceuticals LPProgram year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
48%Serotonin-3 Receptor Antagonist35%Ondansetron Hcl100%Part D≥11 patientsAntidiarrheal microorganisms13%Folic Acid100%Part D<11 patientsNervous system
41%Phenothiazine41%Prochlorperazine Maleate100%Part D<11 patientsCancer & immunology
11%Kinase inhibitor11%Tagrisso100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Neoadjuvant Osimertinib for Resectable <i>EGFR</i> -Mutated Non–Small Cell Lung Cancer
Journal of Clinical Oncology
2025 - Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study
Journal of Thoracic Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Kevin Clerkin, MD
NewYork–Presbyterian Hospital
Brandon Swed, MD
NewYork–Presbyterian Hospital
Richard Mayeux, MD
NewYork–Presbyterian Hospital
Lawrence Lenke, MD
NewYork–Presbyterian Hospital
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”